Keyword: Biomarin Pharmaceutical
There's a new medicine atop of pharma's global pricing charts, and it's Spark Therapeutics' Luxturna.
Halfway into 2017, the FDA has beaten last year's drug-approvals tally with a crop featuring controversy, sales firepower and one very high price.
Orphan drug sales have nearly doubled since 2008, a trend set to continue through 2022 as companies increasingly focus on rare disease meds.
BioMarin’s Cork, Ireland, bulk biologic manufacturing facility has FDA approval to produce an ingredient of Vimizim used to treat Morquio syndrome.
How will Novartis price its CAR-T med if and when it wins an FDA nod? That's what the drugmaker is trying to figure out.
BioMarin scored FDA backing for its orphan drug Brineura, now approved to treat the ultrarare CLN2 disease.
Children with a rare, devastating brain disease may soon have their first treatment option in BioMarin’s Brineura.
When one M&A door closes, many windows open. After Pfizer wrapped up a $14B Medivation buy Monday, investors bid up BioMarin, Incyte and more as likely follow-up targets.
The second-guessing has begun: Would Sanofi have had a shot at winning Medivation if it hadn’t gone hostile so quickly?
BioMarin shares climbed more than 10% Thursday on talk of a potential takeover. And if that scenario sounds familiar, that’s because it is.